Twist Bioscience Corporation Common Stock (TWST) Financial Statements
Historical financial data — 30 statements covering FY2019–FY2025
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-base...
Twist Bioscience Corporation Common Stock's revenue increased 20.3% year over year, from $313.0M to $376.6M.
Net income increased 62.8% over the same period, from $-208.7M to $-77.7M.
Over the 6-year period from FY2019 to FY2025, revenue grew by 592% in total.
Operating cash flow grew 25.7% to $-47.6M.
Twist Bioscience Corporation Common Stock maintains a negative net profit margin of -20.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $81.5M+8.2% | $-85.6M | $35.3M | $-88.9M | $-6.4M | $638.1M | N/A | $491.1M |
| Q4 FY2024 | $84.7M+4.0% | $-34.7M | $38.2M | $-36.0M | $-15.3M | $614.3M | N/A | $472.7M |
| Q1 FY2025 | $88.7M+4.7% | $-31.6M | $42.8M | $-34.6M | $-21.4M | $608.6M | N/A | $455.9M |
| Q2 FY2025 | $92.8M+4.6% | $-39.3M | $46.0M | $-41.6M | $-13.0M | $595.6M | N/A | $440.1M |
| Q3 FY2025 | $96.1M+3.5% | $20.4M | $51.3M | $-30.1M | $-1.4M | $643.6M | N/A | $478.2M |
| Q4 FY2025 | $99.0M+3.1% | $-27.1M | $50.8M | $-29.9M | $-11.8M | $641.9M | N/A | $473.0M |
| Q1 FY2026 | $103.7M+4.7% | $-30.5M | $54.0M | $-32.9M | $-24.8M | $638.1M | N/A | $456.1M |
| Q2 FY2026 | $110.7M+6.8% | $-44.0M | $57.1M | $-45.9M | $-17.6M | $676.2M | N/A | $455.1M |
Balance Sheet Summary (Latest Period)
Twist Bioscience Corporation Common Stock (TWST) Financial Statements & Revenue History
Twist Bioscience Corporation Common Stock (TWST) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $184.05 with a market capitalization of $12. This page provides 30 historical financial statements for Twist Bioscience Corporation Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Twist Bioscience Corporation Common Stock reported revenue of $377 million, representing 20.3% year-over-year growth. The net profit margin of -20.6% indicates the company is currently unprofitable..
TWST Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Twist Bioscience Corporation Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether TWST is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track TWST's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Twist Bioscience Corporation Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of TWST's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use TWST Financial Data
Investors use Twist Bioscience Corporation Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare TWST's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how TWST's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View TWST's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Twist Bioscience Corporation Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.TWST trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.